BiotechTube

Liraglutide + Sugar Pill

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Insulin Resistance

Conditions

Insulin Resistance

Trial Timeline

Mar 1, 2013 → Nov 1, 2023

NCT ID
NCT02403284

About Liraglutide + Sugar Pill

Liraglutide + Sugar Pill is a approved stage product being developed by Novo Nordisk for Insulin Resistance. The current trial status is completed. This product is registered under clinical trial identifier NCT02403284. Target conditions include Insulin Resistance.

What happened to similar drugs?

6 of 20 similar drugs in Insulin Resistance were approved

Approved (6) Terminated (1) Active (14)
🔄AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
🔄Dapagliflozin 10 mg + Placebo tabletAstraZenecaPhase 3
✅SaxagliptinAstraZenecaApproved
🔄AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
🔄sitagliptin + Comparator: glimepiride + open-label metforminMerckPhase 3
✅sitagliptinMerckApproved
🔄sitagliptin phosphateMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02403284ApprovedCompleted

Competing Products

20 competing products in Insulin Resistance

See all competitors
ProductCompanyStageHype Score
naveglitazarEli LillyPhase 2
35
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
40
Dapagliflozin 10 mg + Placebo tabletAstraZenecaPhase 3
40
Placebo 0.01 mL + Placebo 0.02 mL + Placebo 0.03 mL + Placebo 0.04 mL + AC2993 2.5 mcg + AC2993 5.0 mcg + AC2993 7.5 mcg + AC2993 10.0 mcgAstraZenecaPhase 2
35
Atropine + Physostigmine + Placebo SodiumAstraZenecaPhase 1
29
SaxagliptinAstraZenecaApproved
43
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
40
Pramlintide acetateAstraZenecaPhase 2
35
sitagliptin + Comparator: glimepiride + open-label metforminMerckPhase 3
40
sitagliptinMerckApproved
35
sitagliptin phosphateMerckPhase 3
40
MK-1006 + PlaceboMerckPhase 1
29
Comparator: Placebo + Sitagliptin + VogliboseMerckPhase 3
40
sitagliptin phosphate + Comparator: metformin + Comparator: metformin + Comparator: Antidiabetic Standard of CareMerckPhase 3
40
Placebo + MK-0941MerckPhase 1
29
Placebo + PrednisoloneMerckPre-clinical
26
Comparator: exenatide + Comparator: exenatide + Comparator: PlaceboMerckPhase 1
29
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
39
sitagliptin phosphate + Comparator: Placebo + Comparator: SitagliptinMerckPhase 2
35
sitagliptin phosphateMerckPhase 1
29